230 related articles for article (PubMed ID: 8618369)
1. Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.
Feldman M
JAMA; 1996 May; 275(18):1428-31. PubMed ID: 8618369
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidity.
Netzer P; Brabetz-Höfliger A; Bründler R; Flogerzi B; Hüsler J; Halter F
Aliment Pharmacol Ther; 1998 Apr; 12(4):337-42. PubMed ID: 9690722
[TBL] [Abstract][Full Text] [Related]
3. The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration.
Decktor D; Houle JM; Pierce CH
Am J Ther; 1998 Mar; 5(2):97-100. PubMed ID: 10099044
[TBL] [Abstract][Full Text] [Related]
4. Effect of Rennie Liquid versus Maalox Liquid on intragastric pH in a double-blind, randomized, placebo-controlled, triple cross-over study in healthy volunteers.
Hürlimann S; Michel K; Inauen W; Halter F
Am J Gastroenterol; 1996 Jun; 91(6):1173-80. PubMed ID: 8651166
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two antacid preparations on intragastric acidity--a two-centre open randomised cross-over placebo-controlled trial.
Sulz MC; Manz M; Grob P; Meier R; Drewe J; Beglinger C
Digestion; 2007; 75(2-3):69-73. PubMed ID: 17496418
[TBL] [Abstract][Full Text] [Related]
6. Absence of rebound effect with calcium carbonate.
Simoneau G
Eur J Drug Metab Pharmacokinet; 1996; 21(4):351-7. PubMed ID: 9074901
[TBL] [Abstract][Full Text] [Related]
7. Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration.
Gardner JD; Ciociola AA; Robinson M
J Appl Physiol (1985); 2002 Feb; 92(2):427-34. PubMed ID: 11796648
[TBL] [Abstract][Full Text] [Related]
8. Antacid activity of calcium carbonate and hydrotalcite tablets. Comparison between in vitro evaluation using the "artificial stomach-duodenum" model and in vivo pH-metry in healthy volunteers.
Vatier J; Ramdani A; Vitré MT; Mignon M
Arzneimittelforschung; 1994 Apr; 44(4):514-8. PubMed ID: 8011006
[TBL] [Abstract][Full Text] [Related]
9. Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action).
Wilkinson J; Abd-Elaziz K; den Daas I; Wemer J; van Haastert M; Hodgkinson V; Foster M; Coyle C
Drug Dev Ind Pharm; 2019 Mar; 45(3):430-438. PubMed ID: 30470147
[TBL] [Abstract][Full Text] [Related]
10. Clinical study on the influence of a fixed-dose combination of famotidine with calcium carbonate and magnesium hydroxide on the bioavailability of famotidine.
Zhai Q; Fu J; Huang X; Xu B; Yuan YZ; Jiang T; Rong ZX; Chen HZ
Arzneimittelforschung; 2008; 58(11):581-4. PubMed ID: 19137909
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of buffering capacity and acid neutralizing-pH time profile of antacids.
Lin MS; Sun P; Yu HY
J Formos Med Assoc; 1998 Oct; 97(10):704-10. PubMed ID: 9830281
[TBL] [Abstract][Full Text] [Related]
12. Effect of a histamine H2-receptor antagonist, famotidine, on gastric secretion in healthy subjects.
Fukuda Y; Ikezoe I; Okabayashi M; Ohama I; Shimoyama T
Clin Ther; 1987; 9(5):528-35. PubMed ID: 2889528
[TBL] [Abstract][Full Text] [Related]
13. Clinical and laboratory studies of the antacid and raft-forming properties of Rennie alginate suspension.
Tytgat GN; Simoneau G
Aliment Pharmacol Ther; 2006 Mar; 23(6):759-65. PubMed ID: 16556178
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine.
Ikawa K; Shimatani T; Hayato S; Morikawa N; Tazuma S
Biol Pharm Bull; 2007 May; 30(5):1003-6. PubMed ID: 17473452
[TBL] [Abstract][Full Text] [Related]
15. Early and late effects of low-dose famotidine, ranitidine or placebo on pentagastrin-stimulated gastric acid secretion in man.
Grimley CE; West JM; Loft DE; Cottrell J; Mann SG; Stauffer L; Nwokolo CU
Aliment Pharmacol Ther; 1996 Oct; 10(5):743-7. PubMed ID: 8899082
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo.
Grimley CE; Cottrell J; Mann SG; Stauffer L; Nwokolo CU
Aliment Pharmacol Ther; 1997 Oct; 11(5):881-5. PubMed ID: 9354196
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
Adachi K; Komazawa Y; Mihara T; Azumi T; Fujisawa T; Katsube T; Furuta K; Kinoshita Y
J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
[TBL] [Abstract][Full Text] [Related]
18. The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH.
Abe Y; Inamori M; Togawa J; Kikuchi T; Muramatsu K; Chiguchi G; Kawamura H; Kobayashi N; Kirikoshi H; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol; 2004 Jan; 39(1):21-5. PubMed ID: 14767730
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
[TBL] [Abstract][Full Text] [Related]
20. Reduction of postprandial gastric acidity and pepsin concentration by ranitidine and antacids in healthy volunteers.
Berstad A; Rydning A; Kolstad B; Frislid K
Scand J Gastroenterol Suppl; 1981 Jun; 69():67-73. PubMed ID: 6119785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
